Showing 2121-2130 of 2657 results for "".
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Bausch + Lomb and Modulight Announce FDA Approval of Photodynamic Laser for Use with Visudynehttps://modernod.com/news/bausch-lomb-and-modulight-announce-fda-approval-of-ml6710i-photodynamic-laser-for-use-with-bausch-lombs-visudyne/2481374/Bausch + Lomb and Modulight announced that the FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s Visudyne (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choro
- Over 60 Countries and 150 Eye Health Organizations Call on UN to Create a Special Envoy on Visionhttps://modernod.com/news/over-60-countries-and-150-eye-health-organizations-call-on-un-to-create-a-special-envoy-on-vision/2481372/Sixty three countries have written to UN Secretary-General António Guterres calling on him to create a Secretary-General’s "Special Envoy on Vision," according to a news release from the International Agency for the Prevention of Blindness (IAPB). The Envoy w
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmologyhttps://modernod.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider. Terms of the deal were not disclosed. The deal enhances TFS HealthScience's presence in the fields of op
- Horizon Therapeutics Announces Phase 2 Trial Results Evaluating Dazodalibep for the Treatment of Sjögren’s Syndromehttps://modernod.com/news/horizon-therapeutics-announces-phase-2-trial-results-evaluating-dazodalibep-for-the-treatment-of-sjogrens-syndrome/2481357/Horizon Therapeutics announced that the primary endpoint was met for the second population in its phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome. The phase 2 trial evaluated two patient populations and positive results in the first patient po
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill